<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02573493</url>
  </required_header>
  <id_info>
    <org_study_id>201510013</org_study_id>
    <nct_id>NCT02573493</nct_id>
  </id_info>
  <brief_title>Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)</brief_title>
  <acronym>APA</acronym>
  <official_title>Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): &quot;The APA Trial&quot;.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this trial, the objectives are to determine the efficacy and toxicity of induction&#xD;
      chemotherapy (IC) with nab-paclitaxel + cisplatin (Arm 1: AP) and with nab-paclitaxel (Arm 2:&#xD;
      A) alone in patients with HNSCC, and to compare these data to nab-paclitaxel, cisplatin, and&#xD;
      5-FU (APF). The investigators also hypothesize that the high anti-tumor efficacy of&#xD;
      nab-paclitaxel in HNSCC is due to the upregulation of macropinocytosis, a result of the&#xD;
      frequent presence of Ras and PI3K (and epidermal growth factor receptor -EGFR) activation in&#xD;
      this cancer.&#xD;
&#xD;
      Amendment to Add Arm 3:&#xD;
&#xD;
      In this amendment, the investigators retain the AP + concurrent chemoradiation therapy (CRT)&#xD;
      backbone but de-escalate the dose of radiation therapy (RT) from 70 Gy to 42 Gy. The&#xD;
      investigators also plan to administer one dose (vs three) of cisplatin during RT. This novel&#xD;
      treatment approach will be evaluated in patients with HPV-related oropharyngeal squamous cell&#xD;
      carcinoma (OPSCC) (Arm 3), a sub-group with a very favorable prognosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 13, 2016</start_date>
  <completion_date type="Anticipated">December 12, 2029</completion_date>
  <primary_completion_date type="Actual">December 12, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arm 1 and Arm 2: Clinical Complete Response Rate as Measured by Clinical Exam at the Primary Tumor Site</measure>
    <time_frame>Completion of 2 cycles (approximately 6 weeks)</time_frame>
    <description>Assessment of primary tumor site will be done by laryngoscopy performed in the office or in the operating room. The primary tumor response to the first two cycles of induction will be assessed using visual categorical response. The percent change from baseline will be dictated in the ear, nose, and throat (ENT) physician's clinical exam note.&#xD;
Complete response = complete resolution - 100% decrease/minimal residual mucosal abnormality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm 3: Median Percent Weight Loss</measure>
    <time_frame>Completion of treatment (estimated to be 11-15 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arms 1, 2, and 3: Clinical Partial Response Rate as Measured by Clinical Exam at the Primary Tumor Site</measure>
    <time_frame>Completion of 2 cycles (approximately 6 weeks)</time_frame>
    <description>Assessment of primary tumor site will be done by laryngoscopy performed in the office or in the operating room. The primary tumor response to the first two cycles of induction will be assessed using visual categorical response. The percent change from baseline will be dictated in the ENT physician's clinical exam note.&#xD;
Partial response - 99-50% decrease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 1, 2 and 3: Clinical Complete Response Rate as Measured by Clinical Exam at the Involved Regional Nodes</measure>
    <time_frame>Completion of 2 cycles (approximately 6 weeks)</time_frame>
    <description>The involved neck node response to the first two cycles of induction will be assessed using visual categorical response. The neck node measurements will be performed clinically by the treating medical oncology physician and dictated in his/her assessment note.&#xD;
Complete response - complete resolution - 100% decrease/minimal residual mucosal abnormality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 1, 2, and 3: Clinical Partial Response Rate as Measured by Clinical Exam at the Involved Regional Nodes</measure>
    <time_frame>Completion of 2 cycles (approximately 6 weeks)</time_frame>
    <description>The involved neck node response to the first two cycles of induction will be assessed using visual categorical response. The neck node measurements will be performed clinically by the treating medical oncology physician and dictated in his/her assessment note.&#xD;
Partial response - 99%-50% decrease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 1, 2, and 3: Anatomic Tumor Response as Assessed by CT Using RECIST 1.1 Criteria</measure>
    <time_frame>Completion of 2 cycles (approximately 6 weeks)</time_frame>
    <description>-Computed tomography (CT) scan (intravenous contrast preferred) to document and measure the extent of the primary tumor size and involved regional neck nodes. RECIST 1.1 will be used to determine response at the primary tumor site, at the involved regional neck nodes and the radiographic overall tumor response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 1, 2, and 3: Document and Quantify Ki-67 Expression by IHC in Primary Tumor Tissue and Correlate With Clinical Primary Tumor Site Response</measure>
    <time_frame>Completion of 2 cycles (approximately 42 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 1, 2, and 3: Number of Participants Who Experienced a Grade 3-4 Adverse Event as Measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0</measure>
    <time_frame>30 days after completion of treatment (estimated to be 15-25 weeks)</time_frame>
    <description>Compare to those observed with APF with the objective that Arm 1 will be at least 25% lower than the risk of Grade 3-4 AE's during APF (40% decreased to 30%) and Arm 2 will be at least 50% lower than the risk of Grade 3-4 AE's during APF (40% decreased to 20%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 1, 2, and 3: Overall Survival (OS)</measure>
    <time_frame>Through 10 years after completion of treatment (estimated to be 10 years and 22 weeks)</time_frame>
    <description>OS: duration of time from start of treatment to time of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 1, 2, and 3: Disease-free Survival (DFS)</measure>
    <time_frame>Through 10 years after completion of treatment (estimated to be 10 years and 22 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 1, 2, and 3: Progression-free Survival (PFS)</measure>
    <time_frame>Through 10 years after completion of treatment (estimated to be 10 years and 22 weeks)</time_frame>
    <description>â—¦PFS: duration of time from start of treatment to time of progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 1, 2, and 3: Quality of Life as Measured by FACT-H&amp;N and FACT/GOG-NTX-4</measure>
    <time_frame>Through one year after completion of treatment (approximately 74 weeks)</time_frame>
    <description>The FACT/GOG-NTX-4 questionnaire has 4 questions with answers ranging from 0 (Not at all) to 4 (Very Much)&#xD;
The FACT-H&amp;N has 5 sections including physical well-being, social/family well being, emotional well-being, functional well-being, and additional concerns.&#xD;
The answers range from 0 (Not at all) to 4 (Very Much)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Rate</measure>
    <time_frame>Through one year after completion of treatment (approximately 74 weeks)</time_frame>
    <description>OS: duration of time from start of treatment to time of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Rate</measure>
    <time_frame>Through 2 years after completion of treatment (estimated to be 2 years and 22 weeks)</time_frame>
    <description>OS: duration of time from start of treatment to time of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival (DFS) Rate</measure>
    <time_frame>Through one year after completion of treatment (approximately 74 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival (DFS) Rate</measure>
    <time_frame>Through 2 years after completion of treatment (estimated to be 2 years and 22 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) Rate</measure>
    <time_frame>Through one year after completion of treatment (approximately 74 weeks)</time_frame>
    <description>â—¦PFS: duration of time from start of treatment to time of progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) Rate</measure>
    <time_frame>Through 2 years after completion of treatment (estimated to be 2 years and 22 weeks)</time_frame>
    <description>â—¦PFS: duration of time from start of treatment to time of progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm 3: Clinical Complete Response Rate as Measured by Clinical Exam at the Primary Tumor Site</measure>
    <time_frame>Completion of 2 cycles (approximately 6 weeks)</time_frame>
    <description>Assessment of primary tumor site will be done by laryngoscopy performed in the office or in the operating room. The primary tumor response to the first two cycles of induction will be assessed using visual categorical response. The percent change from baseline will be dictated in the ear, nose, and throat (ENT) physician's clinical exam note.&#xD;
Complete response = complete resolution - 100% decrease/minimal residual mucosal abnormality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm 1 and Arm 3: Comparison of Response Rate</measure>
    <time_frame>Completion of 2 cycles (approximately 6 weeks)</time_frame>
    <description>-Stratified for HPV status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm 1 and Arm 3: Comparison of Overall Survival</measure>
    <time_frame>Through 10 years after completion of treatment (estimated to be 10 years and 22 weeks)</time_frame>
    <description>-Stratified for HPV status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm 1 and Arm 3: Comparison of Disease-free Survival</measure>
    <time_frame>Through 10 years after completion of treatment (estimated to be 10 years and 22 weeks)</time_frame>
    <description>-Stratified for HPV status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm 1 and Arm 3: Comparison of Progression-free Survival</measure>
    <time_frame>Through 10 years after completion of treatment (estimated to be 10 years and 22 weeks)</time_frame>
    <description>-Stratified for HPV status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm 1 and Arm 3: Comparison of the Rate of Grade 3/4 Adverse Events</measure>
    <time_frame>30 days after completion of treatment (estimated to be 15-25 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Median Absolute Weight Loss in Arms 2 and 3 to Arm 1</measure>
    <time_frame>From start of radiation treatment through completion of radiation treatment (estimated to be 7 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Median Percent Weight Loss in Arms 2 and 3 to Arm 1</measure>
    <time_frame>From start of radiation treatment through completion of radiation treatment (estimated to be 7 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <condition>Carcinoma, Squamous Cell of the Head and Neck</condition>
  <condition>Cancer of Head and Neck</condition>
  <condition>Cancer of the Head and Neck</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Neoplasms, Head and Neck</condition>
  <arm_group>
    <arm_group_label>Arm 1: nab-Paclitaxel and cisplatin (AP) + CRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment&#xD;
If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.&#xD;
It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: nab-Paclitaxel (A) + CRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment&#xD;
If CR/PR, three more weeks of nab-paclitaxel followed by CRT&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.&#xD;
It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: nab-Paclitaxel and cisplatin (AP) + modified CRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 weeks of nab-paclitaxel and cisplatin (days 1 &amp; 22) followed by primary tumor site assessment&#xD;
If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab&#xD;
If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab&#xD;
CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy&#xD;
Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-Paclitaxel</intervention_name>
    <arm_group_label>Arm 1: nab-Paclitaxel and cisplatin (AP) + CRT</arm_group_label>
    <arm_group_label>Arm 2: nab-Paclitaxel (A) + CRT</arm_group_label>
    <arm_group_label>Arm 3: nab-Paclitaxel and cisplatin (AP) + modified CRT</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Arm 1: nab-Paclitaxel and cisplatin (AP) + CRT</arm_group_label>
    <arm_group_label>Arm 3: nab-Paclitaxel and cisplatin (AP) + modified CRT</arm_group_label>
    <other_name>cis-DDP</other_name>
    <other_name>cis-Platinum II</other_name>
    <other_name>cis-Diamminedichloroplatinum</other_name>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>Arm 2: nab-Paclitaxel (A) + CRT</arm_group_label>
    <other_name>ErbituxÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <arm_group_label>Arm 1: nab-Paclitaxel and cisplatin (AP) + CRT</arm_group_label>
    <arm_group_label>Arm 2: nab-Paclitaxel (A) + CRT</arm_group_label>
    <arm_group_label>Arm 3: nab-Paclitaxel and cisplatin (AP) + modified CRT</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Arms 1 and 3 - AP&#xD;
&#xD;
          -  Diagnosis of selected Stage III or IVa/b HNSCC. Arm 1: T2-T4 primary tumors. Arm 3:&#xD;
             T2T1-T4 primary tumors. Although most of these patients will have regional nodal&#xD;
             disease, patients with no nodal disease will also be eligible.&#xD;
&#xD;
          -  Arm 1: Presence of disease at the oropharynx, hypopharynx, or larynx sub-sites.&#xD;
&#xD;
          -  Arm 3: Presence of disease at the oropharynx sub-sites, which is HPV-related as&#xD;
             verified by p16, a surrogate marker of HPV, or HPV ISH or PCR.&#xD;
&#xD;
          -  Presence of measurable disease defined as lesions that can be accurately measured in&#xD;
             at least one dimension (longest diameter to be recorded) as â‰¥ 10 mm with CT scan.&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control, abstinence) prior to study entry, for&#xD;
             the duration of study participation, and for 3 months after completing treatment.&#xD;
             Should a woman become pregnant or suspect she is pregnant while participating in this&#xD;
             study, she must inform her treating physician immediately.&#xD;
&#xD;
          -  Able to understand and willing to sign an IRB-approved written informed consent&#xD;
             document.&#xD;
&#xD;
          -  ECOG performance status â‰¤ 1.&#xD;
&#xD;
          -  Adequate bone marrow and organ function as defined below:&#xD;
&#xD;
               -  ANC: â‰¥ 1500/mcL.&#xD;
&#xD;
               -  Platelets: &gt; 100,000/mcL.&#xD;
&#xD;
               -  Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
               -  Total bilirubin â‰¤ 1.5 mg/dL&#xD;
&#xD;
               -  AST/ALT/alkaline phosphatase: â‰¤ 2.5 x ULN.&#xD;
&#xD;
               -  Serum creatinine: &lt; 1.5 mg/dL or calculated GFR â‰¥ 75 cc/min. CrCl by Cockcroft&#xD;
                  Gault will be used to estimate GFR.&#xD;
&#xD;
               -  Pulmonary: no requirement for supplemental oxygen and no evidence of&#xD;
                  moderate-severe chronic obstructive pulmonary disease (COPD) by pulmonary&#xD;
                  function tests (PFTs).&#xD;
&#xD;
        Inclusion Criteria: Arm 2 - A&#xD;
&#xD;
          -  Diagnosis of selected Stage III or IVa/b HNSCC. T2-T4 primary tumors. (Patients with&#xD;
             T1 tumors will be excluded). Although most of these patients will have regional nodal&#xD;
             disease, patients with no nodal disease will also be eligible.&#xD;
&#xD;
          -  Presence of disease at the oropharynx, hypopharynx, or larynx sub-sites.&#xD;
&#xD;
          -  Presence of measurable disease defined as lesions that can be accurately measured in&#xD;
             at least one dimension (longest diameter to be recorded) as â‰¥ 10 mm with CT scan.&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control, abstinence) prior to study entry, for&#xD;
             the duration of study participation, and for 3 months after completing treatment.&#xD;
             Should a woman become pregnant or suspect she is pregnant while participating in this&#xD;
             study, she must inform her treating physician immediately.&#xD;
&#xD;
          -  Able to understand and willing to sign an IRB-approved written informed consent&#xD;
             document.&#xD;
&#xD;
          -  ECOG performance status &lt; 3.&#xD;
&#xD;
          -  Adequate bone marrow and organ function as defined below:&#xD;
&#xD;
               -  ANC: â‰¥ 1500/mcL.&#xD;
&#xD;
               -  Platelets: â‰¥ 100,000/mcL.&#xD;
&#xD;
               -  Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
               -  Total bilirubin â‰¤ 2.0 mg/dL&#xD;
&#xD;
               -  AST/ALT/alkaline phosphatase: â‰¤ 5x ULN.&#xD;
&#xD;
               -  Calculated GFR &gt;30 cc/min. CrCl by Cockcroft Gault will be used to estimate GFR.&#xD;
&#xD;
               -  Pulmonary: patients with a requirement for supplemental oxygen or evidence of&#xD;
                  moderate-severe COPD by PFTs are permitted to enroll.&#xD;
&#xD;
          -  If a patient fully meets criteria for Arm 1, but has profound hearing loss and the&#xD;
             physician feels that the patient should not receive Cisplatin, the patient will be&#xD;
             eligible for Arm 2.&#xD;
&#xD;
          -  If a patient fully meets criteria for Arm 1, but has a history of solid organ or bone&#xD;
             marrow transplant, the patient will be eligible for Arm 2 (due to contraindications of&#xD;
             Cisplatin with medications the patient is taking due to the transplant).&#xD;
&#xD;
        Exclusion Criteria (Arm 1 and Arm 2)&#xD;
&#xD;
          -  Prior chemotherapy, prior EGFR targeted therapy, or prior radiation therapy for HNSCC.&#xD;
&#xD;
          -  Disease at the nasopharyngeal, sinus, oral cavity, or other sub-site not specified as&#xD;
             eligible.&#xD;
&#xD;
          -  Diagnosis of unknown primary squamous cell carcinoma of the head and neck.&#xD;
&#xD;
          -  History of prior invasive malignancy diagnosed within 3 years prior to study&#xD;
             enrollment; exceptions are malignancies with a negligible risk of metastasis or death&#xD;
             (e.g., expected 5-year OS &gt; 90%) that were treated with an expected curative outcome,&#xD;
             such as squamous cell carcinoma of the skin, in-situ carcinoma of the cervix uteri,&#xD;
             non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental&#xD;
             histological finding of prostate cancer (TNM stage of T1a or T1b)&#xD;
&#xD;
          -  Receiving any other investigational agents.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to any of the agents used in this study.&#xD;
&#xD;
          -  Taking cimetidine or allopurinol. If currently taking either of these medications,&#xD;
             patient must discontinue for one week before receiving treatment with nab-paclitaxel.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             serious infection, symptomatic congestive heart failure, unstable angina pectoris,&#xD;
             cardiac arrhythmia, or serious psychiatric illness/social situations that would limit&#xD;
             compliance with study requirements.&#xD;
&#xD;
          -  Pregnant and/or breastfeeding. A negative serum or urine pregnancy test is required at&#xD;
             screening for all female patients of childbearing potential.&#xD;
&#xD;
          -  Known to be HIV-positive on combination antiretroviral therapy because of the&#xD;
             potential for pharmacokinetic interactions with the study agents. In addition, these&#xD;
             patients are at increased risk of lethal infections when treated with marrow&#xD;
             suppressive therapy. Appropriate studies will be undertaken in patients receiving&#xD;
             combination antiretroviral therapy when indicated.&#xD;
&#xD;
          -  Peripheral neuropathy &gt; grade 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Adkins, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center and Medical Pavilion</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Cancer Center</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 7, 2015</study_first_submitted>
  <study_first_submitted_qc>October 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2015</study_first_posted>
  <results_first_submitted>December 7, 2020</results_first_submitted>
  <results_first_submitted_qc>February 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 2, 2021</results_first_posted>
  <last_update_submitted>February 27, 2021</last_update_submitted>
  <last_update_submitted_qc>February 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 25, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT02573493/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Nab-Paclitaxel and Cisplatin (AP) + CRT</title>
          <description>Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment&#xD;
If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cisplatin (if cannot receive cisplain will receive cetuximab) which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.&#xD;
It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Nab-Paclitaxel (A) + CRT</title>
          <description>Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment&#xD;
If CR/PR, three more weeks of nab-paclitaxel followed by CRT&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.&#xD;
It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
        </group>
        <group group_id="P3">
          <title>Arm 3: Nab-Paclitaxel and Cisplatin (AP) + Modified CRT</title>
          <description>6 weeks of nab-paclitaxel and cisplatin (days 1 &amp; 22) followed by primary tumor site assessment&#xD;
If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab&#xD;
If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab&#xD;
CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy&#xD;
Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study.</description>
        </group>
        <group group_id="P4">
          <title>Not Enrolled in Any Arm</title>
          <description>-Determined to be not eligible after enrollment to study and was therefore not enrolled on any study arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Determined to not be eligible after enrollment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: Nab-Paclitaxel and Cisplatin (AP) + CRT</title>
          <description>Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment&#xD;
If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cisplatin (if cannot receive cisplatin will receive cetuximab) which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.&#xD;
It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Nab-Paclitaxel (A) + CRT</title>
          <description>Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment&#xD;
If CR/PR, three more weeks of nab-paclitaxel followed by CRT&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.&#xD;
It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
        </group>
        <group group_id="B3">
          <title>Arm 3: Nab-Paclitaxel and Cisplatin (AP) + Modified CRT</title>
          <description>6 weeks of nab-paclitaxel and cisplatin (days 1 &amp; 22) followed by primary tumor site assessment&#xD;
If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab&#xD;
If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab&#xD;
CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy&#xD;
Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study.</description>
        </group>
        <group group_id="B4">
          <title>Not Enrolled in Any Arm</title>
          <description>-Determined to be not eligible after enrollment to study and was therefore not enrolled on any study arm.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" lower_limit="42" upper_limit="77"/>
                    <measurement group_id="B2" value="65.5" lower_limit="48" upper_limit="83"/>
                    <measurement group_id="B3" value="61" lower_limit="41" upper_limit="68"/>
                    <measurement group_id="B4" value="62" lower_limit="62" upper_limit="62"/>
                    <measurement group_id="B5" value="61" lower_limit="41" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Arm 1 and Arm 2: Clinical Complete Response Rate as Measured by Clinical Exam at the Primary Tumor Site</title>
        <description>Assessment of primary tumor site will be done by laryngoscopy performed in the office or in the operating room. The primary tumor response to the first two cycles of induction will be assessed using visual categorical response. The percent change from baseline will be dictated in the ear, nose, and throat (ENT) physician's clinical exam note.&#xD;
Complete response = complete resolution - 100% decrease/minimal residual mucosal abnormality</description>
        <time_frame>Completion of 2 cycles (approximately 6 weeks)</time_frame>
        <population>Only participants enrolled in Arm 1 and Arm 2 are evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Nab-Paclitaxel and Cisplatin (AP) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment&#xD;
If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cisplatin (if cannot receive cisplatin will receive cetuximab) which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.&#xD;
It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Nab-Paclitaxel (A) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment&#xD;
If CR/PR, three more weeks of nab-paclitaxel followed by CRT&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.&#xD;
It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Nab-Paclitaxel and Cisplatin (AP) + Modified CRT</title>
            <description>6 weeks of nab-paclitaxel and cisplatin (days 1 &amp; 22) followed by primary tumor site assessment&#xD;
If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab&#xD;
If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab&#xD;
CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy&#xD;
Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm 1 and Arm 2: Clinical Complete Response Rate as Measured by Clinical Exam at the Primary Tumor Site</title>
          <description>Assessment of primary tumor site will be done by laryngoscopy performed in the office or in the operating room. The primary tumor response to the first two cycles of induction will be assessed using visual categorical response. The percent change from baseline will be dictated in the ear, nose, and throat (ENT) physician's clinical exam note.&#xD;
Complete response = complete resolution - 100% decrease/minimal residual mucosal abnormality</description>
          <population>Only participants enrolled in Arm 1 and Arm 2 are evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Arm 3: Median Percent Weight Loss</title>
        <time_frame>Completion of treatment (estimated to be 11-15 weeks)</time_frame>
        <population>Only participants enrolled in Arm 3 are evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Nab-Paclitaxel and Cisplatin (AP) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment&#xD;
If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.&#xD;
It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Nab-Paclitaxel (A) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment&#xD;
If CR/PR, three more weeks of nab-paclitaxel followed by CRT&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.&#xD;
It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Nab-Paclitaxel and Cisplatin (AP) + Modified CRT</title>
            <description>6 weeks of nab-paclitaxel and cisplatin (days 1 &amp; 22) followed by primary tumor site assessment&#xD;
If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab&#xD;
If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab&#xD;
CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy&#xD;
Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm 3: Median Percent Weight Loss</title>
          <population>Only participants enrolled in Arm 3 are evaluable for this outcome measure.</population>
          <units>percentage of weight loss</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="6.7" lower_limit="2.2" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arms 1, 2, and 3: Clinical Partial Response Rate as Measured by Clinical Exam at the Primary Tumor Site</title>
        <description>Assessment of primary tumor site will be done by laryngoscopy performed in the office or in the operating room. The primary tumor response to the first two cycles of induction will be assessed using visual categorical response. The percent change from baseline will be dictated in the ENT physician's clinical exam note.&#xD;
Partial response - 99-50% decrease</description>
        <time_frame>Completion of 2 cycles (approximately 6 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Nab-Paclitaxel and Cisplatin (AP) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment&#xD;
If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.&#xD;
It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Nab-Paclitaxel (A) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment&#xD;
If CR/PR, three more weeks of nab-paclitaxel followed by CRT&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.&#xD;
It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Nab-Paclitaxel and Cisplatin (AP) + Modified CRT</title>
            <description>6 weeks of nab-paclitaxel and cisplatin (days 1 &amp; 22) followed by primary tumor site assessment&#xD;
If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab&#xD;
If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab&#xD;
CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy&#xD;
Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Arms 1, 2, and 3: Clinical Partial Response Rate as Measured by Clinical Exam at the Primary Tumor Site</title>
          <description>Assessment of primary tumor site will be done by laryngoscopy performed in the office or in the operating room. The primary tumor response to the first two cycles of induction will be assessed using visual categorical response. The percent change from baseline will be dictated in the ENT physician's clinical exam note.&#xD;
Partial response - 99-50% decrease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arms 1, 2 and 3: Clinical Complete Response Rate as Measured by Clinical Exam at the Involved Regional Nodes</title>
        <description>The involved neck node response to the first two cycles of induction will be assessed using visual categorical response. The neck node measurements will be performed clinically by the treating medical oncology physician and dictated in his/her assessment note.&#xD;
Complete response - complete resolution - 100% decrease/minimal residual mucosal abnormality</description>
        <time_frame>Completion of 2 cycles (approximately 6 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Nab-Paclitaxel and Cisplatin (AP) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment&#xD;
If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.&#xD;
It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Nab-Paclitaxel (A) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment&#xD;
If CR/PR, three more weeks of nab-paclitaxel followed by CRT&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.&#xD;
It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Nab-Paclitaxel and Cisplatin (AP) + Modified CRT</title>
            <description>6 weeks of nab-paclitaxel and cisplatin (days 1 &amp; 22) followed by primary tumor site assessment&#xD;
If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab&#xD;
If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab&#xD;
CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy&#xD;
Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Arms 1, 2 and 3: Clinical Complete Response Rate as Measured by Clinical Exam at the Involved Regional Nodes</title>
          <description>The involved neck node response to the first two cycles of induction will be assessed using visual categorical response. The neck node measurements will be performed clinically by the treating medical oncology physician and dictated in his/her assessment note.&#xD;
Complete response - complete resolution - 100% decrease/minimal residual mucosal abnormality</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arms 1, 2, and 3: Clinical Partial Response Rate as Measured by Clinical Exam at the Involved Regional Nodes</title>
        <description>The involved neck node response to the first two cycles of induction will be assessed using visual categorical response. The neck node measurements will be performed clinically by the treating medical oncology physician and dictated in his/her assessment note.&#xD;
Partial response - 99%-50% decrease</description>
        <time_frame>Completion of 2 cycles (approximately 6 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Nab-Paclitaxel and Cisplatin (AP) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment&#xD;
If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.&#xD;
It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Nab-Paclitaxel (A) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment&#xD;
If CR/PR, three more weeks of nab-paclitaxel followed by CRT&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.&#xD;
It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Nab-Paclitaxel and Cisplatin (AP) + Modified CRT</title>
            <description>6 weeks of nab-paclitaxel and cisplatin (days 1 &amp; 22) followed by primary tumor site assessment&#xD;
If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab&#xD;
If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab&#xD;
CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy&#xD;
Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Arms 1, 2, and 3: Clinical Partial Response Rate as Measured by Clinical Exam at the Involved Regional Nodes</title>
          <description>The involved neck node response to the first two cycles of induction will be assessed using visual categorical response. The neck node measurements will be performed clinically by the treating medical oncology physician and dictated in his/her assessment note.&#xD;
Partial response - 99%-50% decrease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arms 1, 2, and 3: Anatomic Tumor Response as Assessed by CT Using RECIST 1.1 Criteria</title>
        <description>-Computed tomography (CT) scan (intravenous contrast preferred) to document and measure the extent of the primary tumor size and involved regional neck nodes. RECIST 1.1 will be used to determine response at the primary tumor site, at the involved regional neck nodes and the radiographic overall tumor response.</description>
        <time_frame>Completion of 2 cycles (approximately 6 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Nab-Paclitaxel and Cisplatin (AP) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment&#xD;
If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.&#xD;
It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Nab-Paclitaxel (A) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment&#xD;
If CR/PR, three more weeks of nab-paclitaxel followed by CRT&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.&#xD;
It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Nab-Paclitaxel and Cisplatin (AP) + Modified CRT</title>
            <description>6 weeks of nab-paclitaxel and cisplatin (days 1 &amp; 22) followed by primary tumor site assessment&#xD;
If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab&#xD;
If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab&#xD;
CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy&#xD;
Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Arms 1, 2, and 3: Anatomic Tumor Response as Assessed by CT Using RECIST 1.1 Criteria</title>
          <description>-Computed tomography (CT) scan (intravenous contrast preferred) to document and measure the extent of the primary tumor size and involved regional neck nodes. RECIST 1.1 will be used to determine response at the primary tumor site, at the involved regional neck nodes and the radiographic overall tumor response.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arms 1, 2, and 3: Document and Quantify Ki-67 Expression by IHC in Primary Tumor Tissue and Correlate With Clinical Primary Tumor Site Response</title>
        <time_frame>Completion of 2 cycles (approximately 42 days)</time_frame>
        <population>The data was not collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Nab-Paclitaxel and Cisplatin (AP) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment&#xD;
If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.&#xD;
It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Nab-Paclitaxel (A) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment&#xD;
If CR/PR, three more weeks of nab-paclitaxel followed by CRT&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.&#xD;
It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Nab-Paclitaxel and Cisplatin (AP) + Modified CRT</title>
            <description>6 weeks of nab-paclitaxel and cisplatin (days 1 &amp; 22) followed by primary tumor site assessment&#xD;
If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab&#xD;
If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab&#xD;
CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy&#xD;
Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Arms 1, 2, and 3: Document and Quantify Ki-67 Expression by IHC in Primary Tumor Tissue and Correlate With Clinical Primary Tumor Site Response</title>
          <population>The data was not collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arms 1, 2, and 3: Number of Participants Who Experienced a Grade 3-4 Adverse Event as Measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0</title>
        <description>Compare to those observed with APF with the objective that Arm 1 will be at least 25% lower than the risk of Grade 3-4 AE's during APF (40% decreased to 30%) and Arm 2 will be at least 50% lower than the risk of Grade 3-4 AE's during APF (40% decreased to 20%).</description>
        <time_frame>30 days after completion of treatment (estimated to be 15-25 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Nab-Paclitaxel and Cisplatin (AP) Induction</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment&#xD;
If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Nab-Paclitaxel (A) Induction</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment&#xD;
If CR/PR, three more weeks of nab-paclitaxel followed by CRT&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Nab-Paclitaxel and Cisplatin (AP) Induction</title>
            <description>6 weeks of nab-paclitaxel and cisplatin (days 1 &amp; 22) followed by primary tumor site assessment&#xD;
If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab&#xD;
If SD/PD: undergo surgery if candidate followed by CRT</description>
          </group>
          <group group_id="O4">
            <title>Arm 1 CRT: Cisplatin + Radiation Therapy</title>
            <description>CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.&#xD;
It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O5">
            <title>Arm 1 &amp; 2 ERT: Cetuximab + Radiation Therapy</title>
            <description>CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.&#xD;
It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O6">
            <title>Arm 3 CR: Cisplatin + Radiation Therapy</title>
            <description>CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy&#xD;
Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Arms 1, 2, and 3: Number of Participants Who Experienced a Grade 3-4 Adverse Event as Measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0</title>
          <description>Compare to those observed with APF with the objective that Arm 1 will be at least 25% lower than the risk of Grade 3-4 AE's during APF (40% decreased to 30%) and Arm 2 will be at least 50% lower than the risk of Grade 3-4 AE's during APF (40% decreased to 20%).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arms 1, 2, and 3: Overall Survival (OS)</title>
        <description>OS: duration of time from start of treatment to time of death from any cause</description>
        <time_frame>Through 10 years after completion of treatment (estimated to be 10 years and 22 weeks)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arms 1, 2, and 3: Disease-free Survival (DFS)</title>
        <time_frame>Through 10 years after completion of treatment (estimated to be 10 years and 22 weeks)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arms 1, 2, and 3: Progression-free Survival (PFS)</title>
        <description>â—¦PFS: duration of time from start of treatment to time of progression or death, whichever occurs first.</description>
        <time_frame>Through 10 years after completion of treatment (estimated to be 10 years and 22 weeks)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arms 1, 2, and 3: Quality of Life as Measured by FACT-H&amp;N and FACT/GOG-NTX-4</title>
        <description>The FACT/GOG-NTX-4 questionnaire has 4 questions with answers ranging from 0 (Not at all) to 4 (Very Much)&#xD;
The FACT-H&amp;N has 5 sections including physical well-being, social/family well being, emotional well-being, functional well-being, and additional concerns.&#xD;
The answers range from 0 (Not at all) to 4 (Very Much)</description>
        <time_frame>Through one year after completion of treatment (approximately 74 weeks)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Rate</title>
        <description>OS: duration of time from start of treatment to time of death from any cause</description>
        <time_frame>Through one year after completion of treatment (approximately 74 weeks)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Rate</title>
        <description>OS: duration of time from start of treatment to time of death from any cause</description>
        <time_frame>Through 2 years after completion of treatment (estimated to be 2 years and 22 weeks)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival (DFS) Rate</title>
        <time_frame>Through one year after completion of treatment (approximately 74 weeks)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival (DFS) Rate</title>
        <time_frame>Through 2 years after completion of treatment (estimated to be 2 years and 22 weeks)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) Rate</title>
        <description>â—¦PFS: duration of time from start of treatment to time of progression or death, whichever occurs first.</description>
        <time_frame>Through one year after completion of treatment (approximately 74 weeks)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) Rate</title>
        <description>â—¦PFS: duration of time from start of treatment to time of progression or death, whichever occurs first.</description>
        <time_frame>Through 2 years after completion of treatment (estimated to be 2 years and 22 weeks)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm 3: Clinical Complete Response Rate as Measured by Clinical Exam at the Primary Tumor Site</title>
        <description>Assessment of primary tumor site will be done by laryngoscopy performed in the office or in the operating room. The primary tumor response to the first two cycles of induction will be assessed using visual categorical response. The percent change from baseline will be dictated in the ear, nose, and throat (ENT) physician's clinical exam note.&#xD;
Complete response = complete resolution - 100% decrease/minimal residual mucosal abnormality</description>
        <time_frame>Completion of 2 cycles (approximately 6 weeks)</time_frame>
        <population>Only participants enrolled in Arm 3 are evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Nab-Paclitaxel and Cisplatin (AP) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment&#xD;
If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.&#xD;
It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Nab-Paclitaxel (A) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment&#xD;
If CR/PR, three more weeks of nab-paclitaxel followed by CRT&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.&#xD;
It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Nab-Paclitaxel and Cisplatin (AP) + Modified CRT</title>
            <description>6 weeks of nab-paclitaxel and cisplatin (days 1 &amp; 22) followed by primary tumor site assessment&#xD;
If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab&#xD;
If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab&#xD;
CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy&#xD;
Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm 3: Clinical Complete Response Rate as Measured by Clinical Exam at the Primary Tumor Site</title>
          <description>Assessment of primary tumor site will be done by laryngoscopy performed in the office or in the operating room. The primary tumor response to the first two cycles of induction will be assessed using visual categorical response. The percent change from baseline will be dictated in the ear, nose, and throat (ENT) physician's clinical exam note.&#xD;
Complete response = complete resolution - 100% decrease/minimal residual mucosal abnormality</description>
          <population>Only participants enrolled in Arm 3 are evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm 1 and Arm 3: Comparison of Response Rate</title>
        <description>-Stratified for HPV status</description>
        <time_frame>Completion of 2 cycles (approximately 6 weeks)</time_frame>
        <population>Data was not collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Nab-Paclitaxel and Cisplatin (AP) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment&#xD;
If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.&#xD;
It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Nab-Paclitaxel (A) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment&#xD;
If CR/PR, three more weeks of nab-paclitaxel followed by CRT&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.&#xD;
It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Nab-Paclitaxel and Cisplatin (AP) + Modified CRT</title>
            <description>6 weeks of nab-paclitaxel and cisplatin (days 1 &amp; 22) followed by primary tumor site assessment&#xD;
If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab&#xD;
If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab&#xD;
CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy&#xD;
Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm 1 and Arm 3: Comparison of Response Rate</title>
          <description>-Stratified for HPV status</description>
          <population>Data was not collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm 1 and Arm 3: Comparison of Overall Survival</title>
        <description>-Stratified for HPV status</description>
        <time_frame>Through 10 years after completion of treatment (estimated to be 10 years and 22 weeks)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm 1 and Arm 3: Comparison of Disease-free Survival</title>
        <description>-Stratified for HPV status</description>
        <time_frame>Through 10 years after completion of treatment (estimated to be 10 years and 22 weeks)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm 1 and Arm 3: Comparison of Progression-free Survival</title>
        <description>-Stratified for HPV status</description>
        <time_frame>Through 10 years after completion of treatment (estimated to be 10 years and 22 weeks)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm 1 and Arm 3: Comparison of the Rate of Grade 3/4 Adverse Events</title>
        <time_frame>30 days after completion of treatment (estimated to be 15-25 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Nab-Paclitaxel and Cisplatin (AP) Induction</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment&#xD;
If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.</description>
          </group>
          <group group_id="O2">
            <title>Arm 3: Nab-Paclitaxel and Cisplatin (AP) Induction</title>
            <description>6 weeks of nab-paclitaxel and cisplatin (days 1 &amp; 22) followed by primary tumor site assessment&#xD;
If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab&#xD;
If SD/PD: undergo surgery if candidate followed by CRT</description>
          </group>
          <group group_id="O3">
            <title>Arm 1 CRT: Cisplatin + Radiation Therapy</title>
            <description>CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.&#xD;
It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O4">
            <title>Arm 3 CR: Cisplatin + Radiation Therapy</title>
            <description>CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy&#xD;
Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm 1 and Arm 3: Comparison of the Rate of Grade 3/4 Adverse Events</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Median Absolute Weight Loss in Arms 2 and 3 to Arm 1</title>
        <time_frame>From start of radiation treatment through completion of radiation treatment (estimated to be 7 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Nab-Paclitaxel and Cisplatin (AP) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment&#xD;
If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.&#xD;
It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Nab-Paclitaxel (A) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment&#xD;
If CR/PR, three more weeks of nab-paclitaxel followed by CRT&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.&#xD;
It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Nab-Paclitaxel and Cisplatin (AP) + Modified CRT</title>
            <description>6 weeks of nab-paclitaxel and cisplatin (days 1 &amp; 22) followed by primary tumor site assessment&#xD;
If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab&#xD;
If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab&#xD;
CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy&#xD;
Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Median Absolute Weight Loss in Arms 2 and 3 to Arm 1</title>
          <units>kilograms</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" lower_limit="3.1" upper_limit="20.8"/>
                    <measurement group_id="O2" value="5.2" lower_limit="4.9" upper_limit="14.6"/>
                    <measurement group_id="O3" value="7.0" lower_limit="1.7" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Median Percent Weight Loss in Arms 2 and 3 to Arm 1</title>
        <time_frame>From start of radiation treatment through completion of radiation treatment (estimated to be 7 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Nab-Paclitaxel and Cisplatin (AP) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment&#xD;
If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.&#xD;
It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Nab-Paclitaxel (A) + CRT</title>
            <description>Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment&#xD;
If CR/PR, three more weeks of nab-paclitaxel followed by CRT&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.&#xD;
CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.&#xD;
It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Nab-Paclitaxel and Cisplatin (AP) + Modified CRT</title>
            <description>6 weeks of nab-paclitaxel and cisplatin (days 1 &amp; 22) followed by primary tumor site assessment&#xD;
If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab&#xD;
If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab&#xD;
CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy&#xD;
Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Median Percent Weight Loss in Arms 2 and 3 to Arm 1</title>
          <units>median percent of weight loss</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="6.7" upper_limit="11.2"/>
                    <measurement group_id="O2" value="6.6" lower_limit="2.6" upper_limit="8.1"/>
                    <measurement group_id="O3" value="6.7" lower_limit="2.2" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>-Adverse events were collected from start of treatment through 30 days following last day of study treatment. -All-cause mortality was collected from start of treatment until completion of follow-up (up to 72 months following completion of treatment).</time_frame>
      <desc>-Participants at risk is zero for Other (Not Including Serious) Adverse Events for Arm 1 Follow-up, Arm 2 Follow-up, and Arm 3 Follow-up because adverse events were not collected in the follow-up period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: Nab-Paclitaxel and Cisplatin (AP) Induction</title>
          <description>Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment&#xD;
If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: Nab-Paclitaxel (A) Induction</title>
          <description>Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment&#xD;
If CR/PR, three more weeks of nab-paclitaxel followed by CRT&#xD;
If &lt;PR, move directly to CRT if not surgical candidates.</description>
        </group>
        <group group_id="E3">
          <title>Arm 3: Nab-Paclitaxel and Cisplatin (AP) Induction</title>
          <description>6 weeks of nab-paclitaxel and cisplatin (days 1 &amp; 22) followed by primary tumor site assessment&#xD;
If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab&#xD;
If SD/PD: undergo surgery if candidate followed by CRT</description>
        </group>
        <group group_id="E4">
          <title>Arm 1 CRT: Cisplatin + Radiation Therapy</title>
          <description>CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.&#xD;
It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
        </group>
        <group group_id="E5">
          <title>Arm 1 &amp; 2 ERT: Cetuximab + Radiation Therapy</title>
          <description>CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.&#xD;
It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk.</description>
        </group>
        <group group_id="E6">
          <title>Arm 3 CR: Cisplatin + Radiation Therapy</title>
          <description>CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy&#xD;
Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study.</description>
        </group>
        <group group_id="E7">
          <title>Arm 1: Nab-Paclitaxel+Cisplatin+CRT Follow-up</title>
          <description>-Follow-up time period of up to 72 months post-completion of therapy</description>
        </group>
        <group group_id="E8">
          <title>Arm 2: Nab-Paclitaxel + ERT Follow-up</title>
          <description>-Follow-up time period of up to 72 months post-completion of therapy</description>
        </group>
        <group group_id="E9">
          <title>Arm 3: Nab-Paclitaxel+Cisplatin+Modified CRT Follow-up</title>
          <description>-Follow-up time period of up to 72 months post-completion of therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac/heart pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Malabsorption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction - cetuximab</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Blood infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Death due to disease progression NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Bladder obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Throat/pharynx/larynx pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chest/thorax pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Mitral valve prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Systolic murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hearing (with baseline audiogram)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hearing (without monitoring program)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Middle ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Eyelid dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Eyelid swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Subconjuctival sclera hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vision photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Watery eyes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Colon polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dental/teeth/periodontal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Distension/bloating</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>GERD</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Malabsorption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Oral cavity hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Oral cavity pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Oropharyngeal erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Salivary gland changes/saliva</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Stoma hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Stomach stricture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Stomatitis (oral cavity)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Teeth (dental caries)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical adenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Face pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>General edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Head and neck edema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Limb edema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain - NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain in bottoms of feet</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Agammaglobulinemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Allergic reaction - cetuximab</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Blood infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Oral thrush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Upper airway NOS infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Viral hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Viral respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dermatitis - chemoradiation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dermatitis - chemotherapy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>G-tube pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>INR</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Neutropenia (ANC)</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>PTT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Diabetes</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>GFR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hyperlipidemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Armpit pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Extremity muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Extremity/limb pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Jaw pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Joint-function</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Knee pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Kyphosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Leg cramps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Lower extremity muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Lower limb generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Muscle pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Soft tissue necrosis - neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Trismus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anoxic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>CNS ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>OCD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Psychosis (bipolar disorder)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>BPH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Chronic renal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Kidney stone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Lower urinary tract symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Polycistic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Urinary hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Bronchospasm/wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Chest/thorax NOS pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Chronic lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hiccoughs</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Larynx hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nose hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nose pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pharynx hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>RSV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Respiratory tract NOS hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sinus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Throat/pharynx/larynx pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Trachea hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Boil</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Cystic lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Ecchymoses</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypopigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rash unexplained</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rash: acneiform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Skin breakdown/decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Ungual infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Douglas R. Adkins, M.D.</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-747-8475</phone>
      <email>dadkins@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

